Abstract
Patient-derived induced pluripotent stem cells (iPSCs) have recently provided a new way to model acute myeloid leukemia (AML) and other myeloid malignancies. Here, we describe methods for the generation of patient-derived iPSCs from leukemia cells and for their subsequent directed in vitro differentiation into hematopoietic cells that recapitulate features of leukemia stem cells (LSCs) and leukemic blasts.
Keywords:
AML; Human induced pluripotent stem cells; Reprogramming; hPSC-hematopoiesis; iPSC disease modeling.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Cellular Reprogramming*
-
Hematopoietic Stem Cells / metabolism*
-
Hematopoietic Stem Cells / pathology
-
Humans
-
Induced Pluripotent Stem Cells / metabolism*
-
Induced Pluripotent Stem Cells / pathology
-
Leukemia, Myeloid, Acute / genetics
-
Leukemia, Myeloid, Acute / metabolism*
-
Leukemia, Myeloid, Acute / pathology
-
Neoplastic Stem Cells / metabolism*
-
Neoplastic Stem Cells / pathology